Urology News

ERA-EDTA Congress

Chronic Kidney Disease Is More Common in the Cancer Population

Publish Date June 11, 2021

In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.

ERA-EDTA Congress

Kidney Stone Risk Higher Among Men Than Women

Publish Date June 11, 2021

Modifiable risk factors accounted for only a fraction of the difference in stone rates between the sexes, according to investigators.

ERA-EDTA Congress

Cardiovascular Risk Differs for Stone Formers With ESKD

Publish Date June 10, 2021

Among patients with nephrolithiasis or urolithiasis, the cardiovascular event rate was 74.4 per 1000 person-years.

Kidney Cancer

Pembrolizumab After RCC Surgery: Potential New Standard of Care

Publish Date June 9, 2021

In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.

Kidney Cancer

Two-Drug Regimen Offers Better Health-Related Quality of Life in Advanced Renal Cell Carcinoma

Publish Date June 9, 2021

The combination of lenvatinib and pembrolizumab improved health-related quality of life.

Prostate Cancer

Targeted Radiotherapy Improves Outcomes in Previously Treated mCRPC

Publish Date June 9, 2021

An investigational targeted radiotherapy added to standard of care improved survival in men with previously treated mCRPC.

Kidney Cancer

Telaglenastat Fails to Improve Outcomes in Previously Treated Metastatic RCC

Publish Date June 9, 2021

Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.

Prostate Cancer

Genomic Landscape of Prostate Cancer Differs by Ancestry, but Frequency of Actionable Alterations Is Similar

Publish Date June 9, 2021

The frequency of targetable alterations was roughly 22% in patients of African ancestry and those of European ancestry.

Prostate Cancer

TAK-700 Improves PFS, Not OS, Compared With Bicalutamide in Metastatic Hormone-Sensitive Prostate Cancer

Publish Date June 9, 2021

TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT.

Kidney Cancer

Combo Continues to Show Superior Efficacy vs Sunitinib in Advanced Clear Cell Renal Cell Carcinoma

Publish Date June 9, 2021

Pembrolizumab plus axitinib improved progression-free and overall survival.